Dr Reddy's Laboratories Ltd
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
524 / 1328
Position in country
1843 / 4091
Return on Assets, %
15.4
-2.7
Net income margin, %
19.1
2.8
EBITDA margin, %
28.4
10.8
Debt to Equity, %
7.4
19.2
Intangible assets and goodwill, %
11
3.6
Revenue CAGR 3Y, %
12
8.5
Total Equity change 1Y, %
20.9
0
Revenue Y, % chg
10.5
0.5
P/E
19
22.7
P/BV
3.7
1.5
P/S
3.6
2.3
EV/S
3.5
2.4
EV/EBITDA
12.1
7.4
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
10.6
51.3
Forward P/E
18.1
15.6
Dividend Yield, %
0.6
1.7
Forward Dividend Yield, %
0.6
0.2
Expected dividend per share
0.4
0
Dividend Ex Date
2023-07-28
Competitors
Ranks
-
Sun Pharmaceutical Industries Ltd
00%
-
Cipla Ltd
00%
-
Torrent Pharmaceuticals Ltd
00%
-
Zydus Lifesciences Ltd
00%
-
Dr Reddy's Laboratories Ltd
00%
-
Alkem Laboratories Ltd
00%
-
Aurobindo Pharma Ltd
00%
-
IPCA Laboratories Ltd
00%
-
Lupin Ltd
00%
-
Mankind Pharma Ltd
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
India
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
12158.5
Ticker
RDY.N
ISIN
US2561352038
IPO date
1986-01-01
Availability on Russian exchanges
Yes
Reporting for
2024-01-30
Date fact. publication of reports
2023-12-31
Company Description
Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: